Evaluation of the efficacy of Aprepitant in vomiting of children with cancer

Phase 3

Recruiting

• Conditions: Malignant cancer.; Agranulocytosis secondary to cancer chemotherapy; D70.1

• Registration Number: IRCT20200204046377N1
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 April 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

age between 6 month to 17 years
Proven malignancy
Chemotherapy regimen with moderate to severe nausea
Lack of nausea and vomiting 24 hours before starting chemotherapy
Lack of known long QT syndrome
Lack of abdominal and pelvic radiation therapy over the past week
No active infection or any uncontrolled disease associated with malignancy
Absence of corticosteroids starting 72 hours prior to chemotherapy for any reason
Lack of Benzodiazepine or opioid for 48 hours

Exclusion Criteria

Sensitivity to the drugs used
Dissatisfaction

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ausea and vomiting. Timepoint: After the intervention for two days. Method of measurement: Appendix link table.